使用血管紧张素转换酶抑制剂与前列腺癌放疗后晚期膀胱毒性风险降低相关
在前列腺癌根治性放疗患者中,两项多中心观察性研究(URWCI 256例、REQUITE 1437例)前瞻性随访至多4年,调整混杂因素后,放疗期间服用血管紧张素转换酶抑制剂(ACEi)者发生血尿的风险降低(HR 0.51,95%CI 0.28–0.94,p=0.030);血压多基因风险评分与高血压相关,但与血尿无关。
要点
- 放疗期间服用ACEi与晚期血尿风险降低相关(HR 0.51,95%CI 0.28–0.94,p=0.030)。
- 该关联经调整既往经尿道前列腺和/或膀胱切除术、心脏病、盆腔淋巴结放疗及膀胱V70后仍存在。
- 血压多基因风险评分与高血压相关,但与血尿无显著关联。
核心结论
- 本研究首次在国际多中心接受盆腔放疗的患者中显示ACEi对膀胱具有放射保护作用。
- 需要机制研究来理解靶向血管紧张素通路如何保护膀胱。
研究设计与样本
- 前列腺癌接受潜在根治性放疗的患者纳入两项多中心观察性研究:URWCI(N=256)和REQUITE(N=1,437)。
- 患者放疗前评估,并前瞻性随访至多四年以观察毒性发生。
- 采用Kaplan-Meier法估计血尿累积概率,多变量分组相对风险模型评估ACEi对血尿时间的影响,调整临床因素并按入组中心分层。
- 在REQUITE和放射基因组学联盟GWAS中检验血压多基因风险评分(PRS)与血尿的关联。
主要发现
- 放疗期间服用ACEi的患者血尿风险降低(HR 0.51,95%CI 0.28–0.94,p=0.030),调整因素包括既往经尿道前列腺和/或膀胱切除术、心脏病、盆腔淋巴结放疗及接受70 Gy的膀胱体积。
- 血压PRS与高血压相关(每标准差比值比1.38,95%CI 1.31–1.46,n=5,288,p<0.001)。
- 血压PRS与血尿无关(每标准差HR 0.96,95%CI 0.87–1.06,n=5,126,p=0.41)。
局限性
- 需要机制研究来理解靶向血管紧张素通路如何保护膀胱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria. We additionally tested genetically-defined hypertension. MATERIALS AND METHODS: Prostate cancer patients undergoing potentially-curative radiotherapy were enrolled onto two multi-center observational studies, URWCI (N = 256) and REQUITE (N = 1,437). Patients were assessed pre-radiotherapy and followed prospectively for development of toxicity for up to four years. The cumulative probability of hematuria was estimated by the Kaplan-Meier method. Multivariable grouped relative risk models assessed the effect of ACEi on time to hematuria adjusting for clinical factors and stratified by enrollment site. A polygenic risk score (PRS) for blood pressure was tested for association with hematuria in REQUITE and our Radiogenomics Consortium GWAS. RESULTS: Patients taking ACEi during radiotherapy had a reduced risk of hematuria (HR 0.51, 95%CI 0.28 to 0.94, p = 0.030) after adjusting for prior transurethral prostate and/or bladder resection, heart disease, pelvic node radiotherapy, and bladder volume receiving 70 Gy, which are associated with hematuria. A blood pressure PRS was associated with hypertension (odds ratio per standard deviation 1.38, 95%CI 1.31 to 1.46, n = 5,288, p < 0.001) but not hematuria (HR per standard deviation 0.96, 95%CI 0.87 to 1.06, n = 5,126, p = 0.41). CONCLUSIONS: Our study is the first to show a radioprotective effect of ACEi on bladder in an international, multi-site study of patients receiving pelvic radiotherapy. Mechanistic studies are needed to understand how targeting the angiotensin pathway protects the bladder.
引用
- Kerns SL, Amidon Morlang A, Lee SM, et al. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiother Oncol. 2022. PMID: 35077710. doi:10.1016/j.radonc.2022.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。